Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 2 , Pages 241-256 , June 2007

Perioperative use of anti-platelet drugs

  • Pierre-Guy Chassot, PD, MER (Staff member)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +41 21 314 2061; Fax: +41 21 314 2004.

References 

  1. Steinbuhl SR, Berger PB, Mann JT, et al. Early and sustained dual oral anti-platelet therapy following percutaneous coronary intervention. A randomized trial (CREDO). JAMA: The Journal of the American Medical Association. 2002;288:2411–2420
  2. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery – a prospective outcome study. British Journal of Anaesthesia. 2006;96:686–693
  3. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies. Part I. Circulation. 2003;108:1664–1672
  4. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334–2351
  5. Dawood MM, Gupta DK, Southern J, et al. Pathology of fatal perioperative myocardial infarction: implications regarding physiopathology and prevention. International Journal of Cardiology. 1996;57:37–44
  6. Landesberg G. The pathophysiology of perioperative myocardial infarction: Facts and perspectives. Journal of Cardiothoracic and Vascular Anesthesia. 2003;17:90–100
  7. Le Manach Y, Perrel A, Coriat P, et al. Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology. 2005;102:885–891
  8. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. The American Journal of Cardiology. 1992;69:729–732
  9. Poldermans D, Boersma E, Bax JJ, et al. Correlation of location of acute myocardial infarct after non-cardiac vascular surgery with preoperative dobutamine echocardiographic findings. The American Journal of Cardiology. 2001;88:1413–1414
  10. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies. Part II. Circulation. 2003;108:1772–1778
  11. Cooke GE, Liu-Stratton Y, Kerketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology. 2006;47:541–546
  12. Hoffmeister HM, Heller W, Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndrome. Thrombosis and Haemostasis. 1999;82:76–79
  13. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934–940
  14. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999;82:265–268
  15. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. Journal of Internal Medicine. 2002;252:283–294
  16. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–1687
  17. Rodondi N, Cornuz J. Place de l'aspirine en prévention primaire des maladies cardio-vasculaires. Revue Médicale Suisse. 2006;2:646–651
  18. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  19. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 supplement):513S–548S
  20. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 supplement):576S–599S
  21. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesthesia and Analgesia. 2001;93:573–580
  22. Serruys PW, Kutryk MJB, Ong ATL. Coronary artery stents. The New England Journal of Medicine. 2006;354:483–495
  23. Yusuf S, Zhao F, Mehta SR, et al., CURE Trial Investigators  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine. 2001;345:494–502
  24. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  25. Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology. 2001;52:333–336
  26. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine. 2001;344:1895–1903
  27. Sreeram GM, Sharma AD, Slaughter TF. Platelet glycoprotein IIb/IIIa antagonists: perioperative implications. Journal of Cardiothoracic and Vascular Anesthesia. 2001;15:237–240
  28. Genoni M, Zeller D, Bertel O, et al. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. The Journal of Thoracic and Cardiovascular Surgery. 2001;122:630–632
  29. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. Journal of the American College of Cardiology. 2006;47:27–33
  30. Labarthe B, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. Journal of the American College of Cardiology. 2005;46:638–645
  31. Wenaweser P, Dörffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to anti-platelet therapy. Journal of the American College of Cardiology. 2005;45:1748–1752
  32. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. Journal of the American College of Cardiology. 2000;35:157–163
  33. Ueda Y, Nanto S, Komamura K, et al. Neointimal coverage of stents in human coronary arteries observed by angioscopy. Journal of the American College of Cardiology. 1994;23:341–346
  34. ACC/AHA guideline update for perioperative cardiovascular evaluation for non-cardiac surgery – executive summary. Circulation. 2002;105:1257–1267
  35. Sattler LF. Recommendations regarding stent selection in relation to the timing of noncardiac surgery postpercutaneous coronary intervention. Catheterization and Cardiovascular Interventions. 2004;63:146–147
  36. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA: The Journal of the American Medical Association. 2005;293:2126–2130
  37. Ong ATL, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. Journal of the American College of Cardiology. 2005;45:2088–2092
  38. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The CHARISMA trial. The New England Journal of Medicine. 2006;354:1706–1717
  39. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. Journal of the American College of Cardiology. 2000;35:1288–1294
  40. Posner KL, Van Norman GA, Chan V. Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Anesthesia and Analgesia. 1999;89:553–560
  41. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate?. Catheterization and Cardiovascular Interventions. 2004;63:141–145
  42. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. Journal of the American College of Cardiology. 2003;42:234–240
  43. Breen P, Lee JW, Pomposelli F, Park KW. Timing of high-risk vascular surgery following coronary artery bypass surgery: a 10-year experience from an academic medical centre. Anaesthesia. 2004;59:422–427
  44. Godet G, Riou B, Bertrand M, et al. Does preoperative coronary angioplasty improve perioperative cardiac outcome?. Anesthesiology. 2005;102:739–746
  45. McFalls EO, Ward HB, Moritz TE, et al. Coronary artery revascularization before elective major vascular surgery. The New England Journal of Medicine. 2004;351:2795–2804
  46. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. The New England Journal of Medicine. 1999;341:1789–1794
  47. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107:1848–1851
  48. Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagulation & Fibrinolysis. 1996;7:80–84
  49. Fatah K, Beving H, Albage A, et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?. European Heart Journal. 1996;17:1362–1366
  50. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Circulation. 2006;113:2803–2809
  51. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of anti-platelet therapy. Lancet. 2004;364:1519–1521
  52. Murphy JT, Brenda GF. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesthesia and Analgesia. 2005;101:971–973
  53. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral anti-platelet agents on acute coronary syndrome. Circulation. 2004;110:2361–2367
  54. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. Journal of the American College of Cardiology. 2005;45:456–459
  55. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its preoperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. Journal of Internal Medicine. 2005;257:399–414
  56. Nutall GA, Santrach PJ, Oliver WC, et al. The predictors of red cell transfusions in total hip arthroplasties. Transfusion. 1996;36:144–149
  57. Manning BJ, O'Brien N, Aravindan S, et al. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury. 2004;35:121–124
  58. Nutall GA, Horlocker TT, Santrach PJ, et al. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine. 2000;25:596–601
  59. Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind placebo-controlled, randomized study. Stroke. 1993;24:1125–1128
  60. Stage J, Jensen JH, Bonding P. Post-tonsillectomy haemorrhage and analgesics. A comparative study of acetylsalicylic acid and paracetamol. Clinical Otolaryngology. 1988;13:201–204
  61. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. British Journal of Urology. 1993;71:574–576
  62. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery. 1994;35:1061–1064
  63. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Critical Care Medicine. 2001;29:2271–2275
  64. Chu MWA, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery?. The Annals of Thoracic Surgery. 2004;78:1536–1541
  65. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006;129:734–737
  66. Qureshi A, Saad M, Zaidat OO, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002;33:1916–1919
  67. Michlig C, Vu DH, Wasserfallen JB, et al. Three years of haemovigilance in a general university hospital. Transfusion Medicine (Oxford, England). 2003;13:63–72
  68. Kearon C, Hirsh J. Current concepts: Management of anticoagulation before and after elective surgery. The New England Journal of Medicine. 1997;336:1506–1511
  69. Pfisterer ME. Late clinical events related to late stent thrombosis after stopping clopidogrel: Prospective randomized comparison between drug-eluting versus bare-metal stenting. Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology. Atlanta, 11-14 March 2006. American Heart Journal. 2006;151:1156–1172
  70. Camenzind E. Safety of drug-eluting stents: insights from meta-analysis. European Society of Cardiology Congress Reports, Hotline I/707009. Barcelona, 3 september 2006.
  71. Kaiser C, Brunner-La-Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet. 2005;366:921–929
  72. Horlocker TT, Wedel DJ, Schroeder DR, et al. Preoperative anti-platelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anesthesia and Analgesia. 1995;80:303–309
  73. Fox J. Spinal and epidural anesthesia and anticoagulation. International Anesthesiology Clinics. 2001;39:51–61
  74. Ollausson K, Magnusdottir H, Lurje L, et al. Anti-ischemic and anti-anginal effects of thoracic epidural anesthesia versus those of conventional medical therapy in the treatment of severe refractory unstable angina pectoris. Circulation. 1997;96:2178–2182
  75. Beattie WS, Badner NH, Choi P. Epidural analgesia reduces postoperative myocardial infarction: a meta-analysis. Anesthesia and Analgesia. 2001;93:853–858
  76. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ (Clinical Research ed.). 2000;321:1493
  77. Norris EJ, Beattie C, Perler BA, et al. Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery. Anesthesiology. 2001;95:1054–1067
  78. Rigg JR, Jamrozik K, Myles PS, et al. Design of the multicenter Australian study of epidural anesthesia and analgesia in major surgery: the MASTER trial. Controlled Clinical Trials. 2000;21:244–256
  79. Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and analgesia on perioperative outcome: a randomized, controlled Veteran Affairs cooperative study. Annals of Surgery. 2001;234:560–569
  80. Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. British Journal of Anaesthesia. 2000;84:450–455
  81. Christopherson R, Beattie C, Frank SM, et al. Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology. 1993;79:422–434
  82. Liu SS, Block BM, Wu CL. Effects of perioperative central neuraxial analgesia on outcome after coronary artery bypass surgery: a meta-analysis. Anesthesiology. 2004;101:153–161
  83. Brilakis ES, Orford JL, Fasseas P, et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. The American Journal of Cardiology. 2005;96:512–514
  84. Agostini P, Biondi-Zoccai GGL, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. European Heart Journal. 2005;26:881–889
  85. Landesberg G, Shatz V, Avopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. Journal of the American College of Cardiology. 2003;42:1547–1554
  86. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A Science Advisory from the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734–739
  87. Hodgson JMcB, Stone GW, Lincoff AM, et al. Late stent thrombosis: Considerations and practical advice for use od drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent Task Force (Clinical Alert). Catheter Cardiovasc Interv. 2007;69:327–333

PII: S1521-6896(07)00018-3

doi: 10.1016/j.bpa.2007.02.002

Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 2 , Pages 241-256 , June 2007

Article Tools

* Image Usage & Resolution